Sumangha, Samuel .
HRN: 07-68-30 Sex: MalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/12/2026
CEFTRIAXONE 1G (VIAL)
04/12/2026
04/18/2026
IV
2G
OD
HEPATOBILIARY INFECTION
Checking Initial Appropriateness
04/16/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/16/2026
04/22/2026
IV
500 Mg
Q8
Intrabdominal Infection
Checking Initial Appropriateness
04/25/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
04/25/2026
05/02/2026
IVTT
4.5g
Q6H
Hepatic Abscess
Checking Initial Appropriateness
04/25/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/25/2026
05/02/2026
IVTT
500mg
Q6H
Hepatic Abscess
Checking Initial Appropriateness
05/04/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/04/2026
05/15/2026
IV
500mg
Q6
Hepatic Abscess
Checking Initial Appropriateness
05/04/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/04/2026
05/22/2026
IV
4.5g
Q6
Hepatic Abscess
Checking Initial Appropriateness
05/15/2026
METRONIDAZOLE 500MG (TAB)
05/15/2026
05/21/2026
ORAL
750mg
Q8
Hepatobilliary Infection
Checking Initial Appropriateness
05/15/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/15/2026
05/21/2026
IV
4.5g
Q6
Hepatobilliary Infection
Checking Initial Appropriateness